NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
